Popular weight loss drug shows promise in children

Danish company Novo Nordisk has announced the success of its clinical trial for the drug "semaglutide," used for weight loss in children. The results showed that 40.4% of children aged 6 to 12 no longer classified as obese after 68 weeks of treatment, provided they adhered to a healthy lifestyle that includes a low-calorie diet and increased physical activity. The medication is administered as a weekly subcutaneous injection and helps reduce appetite and accelerate feelings of fullness, with the potential to lose around 15 kilograms during the course of treatment. These findings open new therapeutic horizons for childhood obesity and highlight the importance of combining the medication with lifestyle modifications for effective weight management.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل